Petar Ozretic1, Ilija Alvir2, Bozena Sarcevic3, Zeljko Vujaskovic4, Zrinka Rendic-Miocevic5, Ana Roguljic5, Lidija Beketic-Oreskovic5,6. 1. 1 Laboratory for Hereditary Cancer, Division of Molecular Medicine, Rudjer Boskovic Institute, Zagreb - Croatia. 2. 2 Department of Gynecologic Oncology, University Hospital for Tumors, Sestre Milosrdnice Clinical Hospital Center, Zagreb - Croatia. 3. 3 Department of Pathology, University Hospital for Tumors, Sestre Milosrdnice Clinical Hospital Center, Zagreb - Croatia. 4. 4 Division of Translational Radiation Sciences, Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, Maryland - USA. 5. 5 Department of Radiotherapy and Internal Oncology, University Hospital for Tumors, Sestre Milosrdnice Clinical Hospital Center, Zagreb - Croatia. 6. 6 Department of Clinical Oncology, University of Zagreb School of Medicine, Zagreb - Croatia.
Abstract
BACKGROUND: The objective of this study was to examine the prognostic significance of carbonic anhydrase IX (CAIX), an endogenous marker for tumor hypoxia; the cellular tumor antigen p53; and the apoptosis regulator Bcl-2, in triple-negative breast cancer (TNBC) patients. METHODS: Immunohistochemically determined expression of CAIX, p53, Bcl-2 and proliferation factor Ki-67, analyzed in 64 paraffin-embedded TNBC tissue samples, was used to assess their relation to clinicopathological variables and prognostic implications for overall survival (OS). RESULTS: Bcl-2 expression was negatively correlated with histological grade of tumor, while expression of p53 was positively correlated with the same clinical variable (p = 0.036 and p = 0.033, respectively). The p53 expression was also positively correlated with tumor size (p = 0.010). Survival analysis showed that patients with high Bcl-2 expression (above cutoff value determined by receiver operator characteristic [ROC] curve analysis) had shorter OS (p = 0.020). The same was observed for patients with tumors larger than 5 cm (p = 0.034) or positive lymph nodes (p = 0.004). Among all 3 examined markers, multivariate analysis showed that only Bcl-2 expression was a strong independent prognostic indicator for decreased OS (hazard ratio [HR] = 15.16, 95% confidence interval [95% CI], 2.881-79.727, p = 0.001). CONCLUSIONS: Elevated expression of Bcl-2 was an independent prognostic factor for poorer OS in TNBC and as such a significant marker for tumor aggressiveness.
BACKGROUND: The objective of this study was to examine the prognostic significance of carbonic anhydrase IX (CAIX), an endogenous marker for tumor hypoxia; the cellular tumor antigen p53; and the apoptosis regulator Bcl-2, in triple-negative breast cancer (TNBC) patients. METHODS: Immunohistochemically determined expression of CAIX, p53, Bcl-2 and proliferation factor Ki-67, analyzed in 64 paraffin-embedded TNBC tissue samples, was used to assess their relation to clinicopathological variables and prognostic implications for overall survival (OS). RESULTS:Bcl-2 expression was negatively correlated with histological grade of tumor, while expression of p53 was positively correlated with the same clinical variable (p = 0.036 and p = 0.033, respectively). The p53 expression was also positively correlated with tumor size (p = 0.010). Survival analysis showed that patients with high Bcl-2 expression (above cutoff value determined by receiver operator characteristic [ROC] curve analysis) had shorter OS (p = 0.020). The same was observed for patients with tumors larger than 5 cm (p = 0.034) or positive lymph nodes (p = 0.004). Among all 3 examined markers, multivariate analysis showed that only Bcl-2 expression was a strong independent prognostic indicator for decreased OS (hazard ratio [HR] = 15.16, 95% confidence interval [95% CI], 2.881-79.727, p = 0.001). CONCLUSIONS: Elevated expression of Bcl-2 was an independent prognostic factor for poorer OS in TNBC and as such a significant marker for tumor aggressiveness.
Entities:
Keywords:
B-cell lymphoma 2; Carbonic anhydrase IX; Ki-67 antigen; Triple-negative breast neoplasms; Tumor biomarkers; Tumor suppressor protein p53
Authors: Chu Van Nguyen; Quang Tien Nguyen; Ha Thi Ngoc Vu; Huyen Thi Phung; Khoa Hong Pham; Roanh Dinh Le Journal: Technol Cancer Res Treat Date: 2020 Jan-Dec
Authors: Hariprasad Thangavel; Carmine De Angelis; Suhas Vasaikar; Raksha Bhat; Mohit Kumar Jolly; Chandandeep Nagi; Chad J Creighton; Fengju Chen; Lacey E Dobrolecki; Jason T George; Tanya Kumar; Noor Mazin Abdulkareem; Sufeng Mao; Agostina Nardone; Mothaffar Rimawi; C Kent Osborne; Michael T Lewis; Herbert Levine; Bing Zhang; Rachel Schiff; Mario Giuliano; Meghana V Trivedi Journal: J Clin Med Date: 2019-10-24 Impact factor: 4.241